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Abstract: Background: Urothelial bladder cancers (UBCs) are distinct in two main molecular 
subtypes, namely basal and luminal type. Subtypes are also diverse in term of immune contexture, 
providing a rationale for patient selection to immunotherapy. Methods: By digital microscopy 
analysis of a muscle-invasive BC (MIBC) cohort, we explored the density and clinical significance 
of CD66b+ tumor-associated-neutrophils (TAN) and CD3+ T cells. Bioinformatics analysis of UBC 
datasets and gene expression analysis of UBC cell lines were additionally performed. Results: Basal 
type BC contained a significantly higher density of CD66b+ TAN compared to the luminal type. This 
finding was validated on TCGA, GSE32894 and GSE124305 datasets by computing a neutrophil 
signature. Of note, basal-type MIBC display a significantly higher level of chemokines (CKs) 
attracting neutrophils. Moreover, pro-inflammatory stimuli significantly up-regulate CXCL1, 
CXCL2 and CXCL8 in 5637 and RT4 UBC cell lines and induce neutrophil chemotaxis. In term of 
survival, a high density of T celsl and TAN was significantly associated to a better outcome, with 
TAN density showing a more limited statistical power and following a non-linear predicting model. 
Conclusions: TAN are recruited in basal type MIBC by pro-inflammatory CKs. This finding 
establishes a groundwork for a better understanding of the UBC immunity and its relevance. 
Keywords: tumor-associated neutrophils; bladder cancer; basal; CD66b; CD3 
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1. Introduction 
Urothelial bladder cancer (UBC) is the ninth most common cancer worldwide [1]. Despite that 
80% of cases are limited to the superficial layers of the urothelium (non-muscle invasive bladder 
cancer, NMIBC) [2], about 20% display a muscle-invasive aggressive disease (MIBC) at the onset and 
a third of them will eventually develop metastasis over time [3]. Radical cystectomy with lymph-
node dissection represents the standard of treatment for operable MIBC; however, 5-year overall 
survival (OS) is 50% or even lower in locally advanced disease [4]. As for unresectable and metastatic 
MIBC, the treatment algorithm is rapidly evolving with the recent approval of immunotherapy 
beyond the first line Platinum-based chemotherapy [5], the latter ensuring a five-year OS of only 13–
22% [6]. Nevertheless, only about 23–26% of patients show objective response with second line 
immunomodulatory agents [7], indicating that a better patient selection is mandatory. 
Recent advances in the understanding of the genomic and transcriptomic landscape of UBC have 
proposed additional windows of intervention based on tumor-cell intrinsic molecular features. 
Specifically, gene expression profile analysis revealed that UBC is an extremely heterogeneous 
disease that can be grouped into two main subtypes, namely basal and luminal type [8]. Molecular 
pathways controlling tumor growth are divergent in basal vs. luminal UBC, thus providing the 
rationale for their different biological behavior [9]. Luminal type UBCs display a hyperplastic well 
differentiated papillary histology at the onset and are frequently enriched with activating mutations 
in HRAS and fibroblast growth factor receptor 3 (FGFR3) [10]. This subgroup could benefit by FGFR3 
targeting, recently approved also in the neoadjuvant setting [11]. Basal type UBCs originate instead 
from flat high-grade precursors including carcinoma in situ (CIS) via inactivation of TP53, RB1 and 
hyper-activation of the transcription factors STAT3, NFKB1 and TP63 in the stem cells of the basal 
layer. These features might account for the more aggressive behavior of basal type UBCs [12]. 
Beyond tumor-cell intrinsic molecular features, the UBC immune contexture can also yield 
information relevant to prognosis and to treatment response, particularly to immunotherapy [13]. Of 
note, luminal and basal subtypes display a different microenvironment in term of immune and 
stromal cells [14–16]; moreover, the recently identified “infiltrated” subtypes display a specific 
immunological signatures [17,18]. Basal type UBCs show a higher level of immunogenicity based on 
a set of observations. Firstly, high grade CIS response to intravesical instillation of Bacillus Calmette-
Guérin (BCG) is highly dependent on immune contexture [19,20]. Secondly, despite some 
controversial data, a high density of tumor infiltrating lymphocytes (TILs) in basal type MIBCs is 
correlated to a better outcome [15,21]. Thirdly, basal-type MIBCs displaying a high density of 
immune infiltration respond better to adjuvant chemotherapy [15], in contrast to luminal-type MIBC 
that do not derive much benefit [22]. However, it should be reminded that a recently identified subset 
of ‘luminal-infiltrated’ may respond to immunotherapy [23]. 
Various immunosuppressive mechanisms affect adaptive T-cell response to cancer, such as the 
well-known PD-1/PD-L1 axis, thus enhancing tumor growth and progression [24]. This has set the 
rationale for PD-1/PD-L1 blockade, with promising results also in patients with advanced UBC 
progressing after platinum-based chemotherapy [25]. At present, PD-L1 expression both on tumor 
cells and infiltrating immune cells is the only accepted predictor of response in UBC [6,25], although 
with a still limited performance in the selection of responders [7,26]. Some evidence shows that the 
tumor mutational burden (TMB), a CD8+ T cell signature, a TGF-β immune suppressive milieu and 
the UBC molecular subtype can predict response to immune check-point inhibitors (ICI) as well, but 
a reliable predictive nomogram is still lacking. Notably, the basal and the luminal-infiltrated subtypes 
have shown the best benefit from ICI compared with other subtypes [23,26], but only 20% of patients 
reached a complete response [5]. 
All these findings suggest that other immune escape mechanisms might be in place in MIBC. 
Among the latter, infiltration by myeloid cells might account for a reduced specific T-cell response. 
Granulocyte population found within the tumor tissues are referred as tumor-associated neutrophils 
(TANs) [27]. In mouse, TANs can be polarized in vitro [28], [29]. N1-type TANs exert anti-tumor 
functions, whereas N2-type TANs are TGF-β-driven and sustain cancer progression. It is still 
unknown whether human TANs display similar polarization. The most recent literature considers 
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neutrophils as a population with potentially pro-inflammatory or anti-inflammatory functions 
showing either a pro-tumoral or an anti-tumoral program, thus partially overcoming the 
dichotomous definition of N1 and N2 cells [30]. Data from large retrospective cancer cohorts [31] 
have supported a pro-tumor function of TANs, with a high TAN tumor density significantly 
associated to a worse outcome [32]. However, emerging data have challenged this view showing 
TANs with anti-tumor activities [33]. Numerous works have proposed a clinical utility of the 
peripheral neutrophil to lymphocytes ratio (NLR) in bladder cancer in term of prognosis [34] and 
recurrence [35] for MIBCs who underwent cystectomy. On the contrary, works on TAN and UBCs 
are very limited. Elevated TANs have been correlated with poor prognosis [36], whereas a lower 
TANs density predict a better response to adjuvant chemotherapy [37]. However, studies adherent 
to analytical standards of immunoscore evaluation of TAN density, are still lacking [38]. 
In this study, we have measured the TAN and TIL density in a retrospective cohort of MIBC by 
applying digital microscopy to CD66b and CD3 stained whole sections. Our findings suggest that 
high density of CD66b+ TAN represent a distinct feature of basal type MIBC. Moreover, based on in 
silico analysis of UBC datasets and in vitro studies on UBC cell lines, we found that TAN-attracting 
chemokines are enriched in basal type UBC. These findings might be of help in patient selection to 
established and novel immunotherapy approaches. 
2. Materials and Methods 
2.1. Patient’s Cohort 
This retrospective study was conducted in compliance with the Helsinki Declaration and with 
policies approved by the Ethics Board of ASST Spedali Civili di Brescia (IRB code: NP 2483/2016 to 
WV). The cohort included previously untreated patients affected by muscle invasive bladder cancer 
(MIBC), treated by cystectomy from 2006 to 2016 in the Department of Urology, ASST Spedali Civili 
di Brescia (Brescia, Italy). Surgical specimens were reviewed and staged according to the TNM 
staging system [39]. Exclusion criteria included any treatment before diagnostic biopsy and 
occurrence of other malignancies. Formalin fixed paraffin-embedded (FFPE) UBC were retrieved 
from the archive of the Department of Pathology, ASST Spedali Civili di Brescia (Brescia, Italy). 
Clinical follow-up data were retrieved from the Department of Urology, ASST Spedali Civili di 
Brescia (Brescia, Italy). 
The analyzed cohort consisted of 84 MIBCs (T category ≥ pT2); classification of MIBCs into 
luminal and basal subtypes is described later. Demographic, histological and clinical findings are 
summarized in Supplementary Table 1. 
2.2. Immunohistochemistry 
Four-micron thick FFPE sections were used for immunohistochemical staining. Heat mediated 
antigen retrieval was performed in a microwave oven and endogenous peroxidase activity was 
quenched using 0.3% hydrogen peroxide (Sigma-Aldrich, Saint-Louis, MO, USA) diluted with 
methanol (Sigma-Aldrich, Saint-Louis, MO, USA). After washing with Tris-Buffered Saline (TBS, 
Sigma-Aldrich, Saint-Louis, MO, USA) solution, slides were incubated with the primary antibody for 
1 h at room temperature and revealed by a 30 min incubation with a horseradish-peroxidase polymer 
(Novolink Polymer Detection System - Leica Biosystems, Wetzlar, Germany), followed by 3,3′-
diaminobenzidine (Leica Biosystems, Wetzlar, Germany) as chromogen. Sections were 
counterstained with Mayer’s haematoxylin (Bioptica). For double immunohistochemical staining, 
after completing the first immune reaction, the second was visualized using Mach 4 MR-AP (Biocare 
Medical, Pacheco, CA, USA), followed by Ferangie Blue (Biocare Medical, Pacheco, CA, USA) as 
chromogen. 
For immunohistochemistry (IHC), primary antibody include: anti-CD66b (clone G10F5, Mouse 
IgM, dilution 1:120, BioLegend, San Diego, CA, USA), anti-CD3 (clone SP7, Rabbit IgG, dilution 1:100, 
Thermo Fisher Scientific, Waltham, MA, USA), anti-CD11b (polyclonal, Rabbit, dilution 1:300, Sigma 
Aldrich, Saint-Louis, MO, USA), anti-CD15 (clone MMA, Mouse IgM, dilution 1:400, BD Biosciences, 
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San Jose, CA, USA) and anti-Arginase-1 (clone SP156, Rabbit IgG, dilution 1:100, Cell Marque, 
Rocklin, CA, USA). 
The classification of MIBCs into subtypes was performed on TURB using a four marker panel 
composed of CK5/6 (basal marker), CK14 (basal marker), CK20 (luminal marker) and UPK2 (luminal 
marker), as previously described [40]; similarly, detailed for pSTAT3 and FOSL1 stain are reported 
in our previous study [40]. 
2.3. Digital Microscopy 
Stained slides were acquired using the Aperio CS2 digital scanner and ScanScope software 
(Leica Biosystems, Wetzlar, Germany). Images were viewed and organized using ImageScope 
software (Leica biosystems, Wetzlar, Germany). Each scanned image was annotated manually and 
IHC Nuclear Image Analysis algorithm was chosen for the analysis. The whole tumor area has been 
considered for the analysis, with the exclusion of necrotic areas. Data are expressed as absolute 
number of CD66b+ or CD3+ cells per mm2. 
2.4. Statistical Analysis 
For histological, clinical and pathological analysis, the qualitative variables were described as 
absolute and relative frequencies; standard descriptive statistics were used for continuous variables, 
expressing means, medians, interquartile ranges (IQR) and standard deviations. Correlation between 
cell population densities were computed using Spearman correlation coefficient. Shapiro–Wilk test 
was applied, normality distribution of continuous variables (immune cells densities) was not 
confirmed and non-parametric test were subsequently used. 
The main survival endpoint was the overall survival (OS), defined as the time between the date 
of the cystectomy and the date of death; progression free survival (PFS), as secondary endpoint, was 
defined as the time between the date of the surgery and the date of recurrence. In the absence of an 
event, survivals were censored at last follow-up visit. Qualitative variables were compared between 
groups using Fisher exact test and quantitative variables by Mann-Whitney or Kruskal-Wallis test 
(followed by p-values adjustment by Dunn’s test for multiple comparisons). Cut-offs in continuous 
predictors for the definition of groups rich (Hi) or poor (Lo) of immune cells were set at the median 
value for each distribution. A tissue neutrophil to lymphocyte ratio (tNLR; CD66b/CD3 counts) 
obtained for each sample was also computed as a variable. Univariate and multivariate survival 
analyses were performed using Cox proportional hazard models; multivariable models were built by 
a backward selection applying Likelihood-ratio test and Akaike information criterion; estimates were 
reported as hazard ratio (HR) with 95% Confidence Intervals (CI95%). Univariate survival curves 
were plotted by the Kaplan-Meier method with covariates adjustment and compared by the Log-rank 
test. 
Survival multivariable models were subsequently built including immune cells densities as 
continuous variables, after log transformation; to account for potential non-linear effects on HR 
penalized splines with degrees of freedom selected via Corrected Akaike’s Information Criterion 
(AICc, [41]) were used. 
For in vitro experiments, UBC cell lines were analyzed using the One-way ANOVA with 
Bonferroni’s correction. 
In all analysis a two-tailed p value < 0.05 was considered significant. GraphPad Prism (San Diego, 
CA, USA), Stata (version 13.0, College Station, Texas, USA) and R (version 3.5.1) were used for 
statistical analysis. 
2.5. Cell Cultures 
RT4 (ATCC® HTB2TM) and 5637 (ATCC® HTB9TM) cell lines were obtained from ATCC-LGC 
Standards Repository (Rockville, USA). 5637 cells were maintained in ATCC-formulated RPMI1640 
Medium (cat. No. A10491-01, GibcoTM for Life Technologies - Thermo Fisher Scientific, Waltham, 
MA, USA). RT4 cells were maintained in ATCC-formulated McCoy’s 5a Medium Modified (cat. no. 
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26600-023, GibcoTM for Life Technologies - Thermo Fisher Scientific, Waltham, MA, USA). All media 
were supplemented with 10% fetal bovine serum (FBS) (cat. no. S0115, Biochrom, Berlin, Germany), 
1% Penicillin/Streptomycin (cat. No. 15070-063, GibcoTM), and the cells were cultured at 37 °C and 
5% CO2. 
One hundred and forty-four-hour STAT3-silenced 5637 cells, as well as untreated 5637 cells and 
RT4 cells, were stimulated with a cocktail of recombinant human TNF-a (20 ng/mL; cat. no. 300-01A), 
recombinant human IL6 (20 ng/mL; cat. no. 200-06), and recombinant human IL1b (20 ng/mL; cat. no. 
200-01B; all from PeproTech, EC, Ltd., London, UK) for 4 h or 24 h. 
2.6. Neutrophil Isolation and Transwell Migration Assay 
Circulating neutrophils were isolated from healthy donors by density gradient centrifugation 
(Ficoll-Paque; GE Healthcare Life Sciences) of whole blood and further purified by negative selection 
using the EasySep neutrophil enrichment kit (StemCell Technologies, Vancouver, Canada) as 
previously described [42]. The purity of isolated neutrophils was > 99.8%, as determined by flow 
cytometry. Neutrophil direct migration (chemotaxis) was measured in Transwell chamber (3 μm; 
Corning Costar), as previously described [43]. Briefly, 100 μL of neutrophil suspensions (2 × 106/mL) 
were added to the top chambers, whereas 600 μL of control medium or tumor-conditioned 
supernatants from luminal-type RT4 or basal-type 5637 UBC cell lines, either unstimulated or treated 
with the pro-inflammatory cytokine cocktail (TNF-a, IL6 and IL1b) for 4 or 24 h (as described above) 
were added to the bottom wells. After 45 min, the plates were spun, the inserts were removed, and 
the number of migrated cells were counted with CyQuant cell proliferation assay kit (Invitrogen 
SRL). Parallel samples were included to determine the signal intensity from the total cell number 
loaded into the Transwell inserts. 
2.7. Quantitative RT-PCR (qRT-PCR) 
CXCL1, CXCL2, CX3CL1 and CXCL8 mRNA targets were quantified by reverse transcription-
polymerase chain reaction (qRT-PCR) assay using the Vii-A 7 Real-Time PCR System (Applied 
Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). Total RNA was extracted from UBC cells 
by TRIzol™ (cat. no. 15596026, Invitrogen™, Thermo Fisher Scientific). The cDNA was synthesized 
by iScript gDNA cDNA Synthesis kit (cat. no. 1725035, Bio-Rad Laboratories Inc., Hercules, CA, 
U.S.A.) from 1 μg of total RNA, in a total volume of 20 μL. One μL of the cDNA synthesis reaction 
was used for the specific amplification of the target transcripts. The Hypoxanthine-guanine 
phosphoribosyltransferase 1 (HPRT1) transcript was used as normalization control. The PCR was 
performed in a total volume of 20 μL with TaqMan® Universal Master Mix II (cat. no. 4369016, 
Applied Biosystems, Thermo Fisher Scientific) and the Gene Expression Assay (Supplementary Table 
S2). The threshold cycle (Ct) was determined for each sample and quantification was performed using 
the comparative Ct method. ΔCt was derived as CtTarget – CtHousekeeping and considered for statistical 
analysis. 
2.8. STAT3 Silencing 
STAT3 (Genbank accession n° NM_139276.2, NM_213662.1, NM_00315.3) and control 
knockdown was obtained using specific-STAT3 siRNA (assay ID S744) and control scrambled-siRNA 
(ca. no. 4390846), obtained from Ambion (Thermo Fischer Scientific, Waltham, MA, USA). Validation 
of si-STAT3 silencing was obtained as previously described. For more details see Benerini Gatta L. et 
al. 2019 [40]. 
2.9. Data Preprocessing and Statistical Analysis of the TCGA, GSE32894 and GSE124305 Datasets 
Raw counts for primary solid tumor samples were downloaded from GDC portal harmonized 
repository using TCGAbiolinks R/Bioconductor package (n = 408 cases). The FFPE samples were 
removed. The duplicated samples counts were averaged (n = 388). The library size normalization 
factors were obtained with the trimmed mean of M-values (TMM) [44] and gene expression was 
Cells 2020, 9, 291 6 of 24 
 
computed as log2-RPKM. GSE32894 and GSE124305 expression values were preprocessed applying 
a quantile normalization and transformed on log scale. 
TCGA and GSE32894 include chemotherapy-naive MIBC [17,18], whereas GSE124305 include 
MIBC cystectomy samples obtained after Neoadjuvant Chemotherapy treatment and containing 
residual tumor. As reported [45], basal and luminal subtypes from this post-treatment cohort express 
a gene signatures consistent with a basal and luminal phenotype comparable to their matched pre-
treatment tumor samples [22]. In all datasets, we have considered only MIBC cases. Moreover, in 
addition to basal and luminal subtypes, each of three datasets includes other molecular subtypes 
based on their immune signature, defined by consensus clustering in each of the three independent 
cohorts. 
Global gene signature (Chemokine or PMN) were computed using single sample gene 
enrichment based on Gene Set Variation Analysis (GSVA) [46]. The neutrophil signature was 
obtained from the study by Newman et al. [47] (Supplementary Table S3). Chemokines with pro-
inflammatory functions have been defined based un published classifications [48] (Supplementary 
Table S3). 
Differential expression among subtypes at gene level for both signatures was evaluated using 
generalized linear modelling [49]. Specifically for TCGA data, negative binomial generalized log-
linear models were applied to read counts while for GSE datasets, ordinary least square models, with 
moderated t-statistics computation [50]. 
Unsupervised hierarchical clustering was performed on expression values using Euclidean 
distance and Ward method [51]. 
A supervised classification algorithm was applied on the three datasets independently to 
ascertain the potential predictive performance of selected signatures on subtypes prediction. We 
adopted a Random Forest (RF) algorithm and estimated its performance based on Out-Of-Bag (OOB) 
error rate. In order to visualize the estimated relationship between samples, we used the proximity 
matrix derived from RF in a hierarchical clustering. 
3. Results 
3.1. Patient Characteristics 
The clinical and pathological findings of the MIBC patient cohort are summarized in Table 1 and 
detailed in Supplementary Table S1. The median age was 72 at surgery. Median follow-up time was 
60 months (CI95% 36; 84). Median overall survival was 65 months (CI95% 25; 92), whereas median 
progression free survival was 27 months (CI95% 10; ∞). During follow-up, 38 patients had recurrence 
and 38 patients died. None of the patients received neo-adjuvant chemo- or immunotherapy. After 
cancer recurrence, none of the patients received additional treatment. The univariate analysis 
confirmed the prognostic significance of the well-known clinical variables as higher age (p = 0.024), 
female gender (p = 0.003), higher pT category (p = 0.003), presence or nodal disease (N+) (p = 0.016), 
and higher Overall Stage (p = 0.002) associated with a worse OS; moreover, a higher pT category (p = 
0.005), presence or nodal disease (N+) (p = 0.015) and higher Overall Stage (p = 0.005) were associated 
with a worse PFS (Table 2). In the cohort, despite the TNM staging system was confirmed to stratify 
prognosis, 23% of patients in stage II experienced recurrence. 
Table 1. Demographic, histological, and clinical data of the MIBC patient cohort. CIS, carcinoma in 
situ; SD, standard deviation; IQR, interquartile range; NA, not available. 
  
Total 
N (%)   
CIS Concomitant 
N (%) 
84 (100)  
  Yes 50 (60) 
Gender  No 34 (40) 
Female 16 (19) Global Stage  
Male 68 (81) II 22 (26) 
Age (years)  III 33 (39) 
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Mean (SD) 70.9 (10.44) IV 29 (35) 
Median (IQR) 72 (14) Subtype  
Stage pT  Luminal 41 (49) 
pT2 25 (30) Basal 20 (24) 
pT3 41 (49) Non-type 23 (27) 
pT4 18 (21) pSTAT3  
Stage pN  Score 0–1 43 (51) 
pN0 57 (68) Score 2–3 41 (49) 
pN1 16 (19) FOSL1  
pN2 10 (12) Score 0–1 19 (23) 
pN3 1 (1) 
Score 2–3 
NA 
22 (26) 
43 (51) 
Table 2. Univariate analysis of clinical and pathological findings related to overall survival and 
progression free survival. tNLR, tissue NLR. 
Clinicopathological  
Variables 
Overall Survival Progression Free Survival 
H.R. (CI 95%) p H.R. (CI 95%) p 
Age (years) 1.04 (1.01–1.08) 0.024 0.99 (0.96–1.02) 0.65 
Gender (F vs. M) 2.93 (1.45–5.94) 0.003 1.94 (0.94–4.00) 0.072 
pT (pT3-4 vs. pT2) 4.21 (1.63–10.85) 0.003 3.54 (1.47–8.55) 0.005 
pN (pN+ vs. pN0) 2.22 (1.16–4.23) 0.016 2.25 (1.17–4.33) 0.015 
CIS (yes vs. no) 0.63 (0.33–1.19) 0.155 0.86 (0.45–1.65) 0.657 
Overall Stage (SIII-IV vs. SII) 5.07 (1.78–14.41) 0.002 3.94 (1.52–10.21) 0.005 
Subtype (basal vs. luminal) 1.3 (0.59–2.87) 0.520 0.70 (0.32–1.55) 0.383 
Subtype (Non-type vs. luminal) 1.66 (0.78–3.53) 0.191 0.73 (0.33–1.60) 0.431 
pSTAT3 (High vs. Low) 1.19 (0.63–2.26) 0.595 0.69 (0.36–1.32) 0.265 
CD66b (Low vs. High) 2.53 (1.30–4.92) 0.006 2.68 (1.37–5.24) 0.004 
CD3 (Low vs. High) 2.62 (1.35–5.08) 0.004 1.69 (0.88–3.22) 0.11 
CD3CD66b Immunoscore  
(LoLo vs. HiHi) 5.27 (2.12–13.11) <0.001 3.95 (1.53–10.16) 0.004 
CD3CD66b Immunoscore  
(LoHi vs. HiHi) 
2.26 (0.79–6.49) 0.13 2.15 (0.75–6.14) 0.155 
CD3CD66b Immunoscore  
(HiLo vs. HiHi) 
2.18 (0.79–6.04) 0.133 3.43 (1.32–8.89) 0.011 
tNLR (CD66b+/CD3+) 1.04 (0.75–1.44) 0.828 1.07 (0.75 –1.53) 0.699 
3.2. CD66b+ TAN and CD3+ T cell Immune-Contexture in Muscle Invasive UBC 
Data on the immune contexture of UBC are scant and limited to the lymphocytic infiltrate, while 
myeloid cells infiltrate has been less characterized. To expand this field, we quantified the density of 
CD3+ T cells and CD66+ TANs in the same retrospective cohort of muscle-invasive UBC (MIBC, n = 
84) (Table 1, Table 2). Complete clinical, pathological and image analysis details of the cohort are 
reported in Supplementary Tables S1 and S4. A representative tissue block of the tumor was used for 
the analysis and representative images are shown in Figure 1A–H. A mean tumor area of 153.7 mm2 
(range from 7.4 mm2 to 420.7 mm2) was obtained. The median density of CD66b+ TANs was 78 
cells/mm2, whereas for CD3+ T cells the median density was 396 cells/mm2 (Figure 2A). The density 
of the two populations showed a significant correlation (RS = 0.28, p = 0.011) (Figure 2B). Based on 
double stain performed on a set (n = 5) of MIBC, CD66b+ co-expressed neutrophils markers including 
CD11b, CD15 and arginase (Figure 2C–H). When compared with pathological and clinical features, 
we found that the density of the CD3+ T cells significantly decreased over UBC progression in term 
of pT category and Overall Stage (Figure 3, Table 3), whereas no correlations where observed for 
CD66+ TAN density. No significant associations were found between tissue NLR (tNLR) and clinical 
variables (Table 3). 
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Figure 1. Representative image analysis for CD66b+ TAN and CD3+ T cells in human MIBC. Sections 
are from four representative human MIBC (case #66, #31, #7 and #46) and stained as labeled and 
counterstained with hematoxylin (A, C, E, G). On the right column, the corresponding processed area 
is shown (B, D, F, H). Case with high and low density of CD66b+ TAN (A and C, respectively) and 
CD3+ T cells (E and G, respectively) are displayed. Images acquired from digital slides using 400× 
magnification have been digitally resized using Adobe Photoshop. 
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Figure 2. Density of CD66b+ TAN and CD3+ T cells and phenotype of TAN in human MIBC. Dot plots 
indicating the density of CD66b+ TAN and CD3+ T cells in the MIBC cohort is reported in (A); the 
correlation between the two variables is illustrated in (B). Sections are from two representative MIBC 
cases (case #70 in C, E and G; case #79 in D, F and H) and stained as labeled, illustrating CD66b+ TAN 
co-expressing neutrophil markers: CD11b, CD15 and ARG. Sections are counterstained with 
hematoxylin. Magnification 400× (scale bar 50 micron). 
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Figure 3. Clinical correlation of CD66b+ TAN and CD3+ T cells densities in human MIBC. Dot plots 
showing CD3+ T cells (A,B) and CD66b+ TAN (C,D) density distributions among different pT 
categories and Overall Stages in the MIBC cohort. p values were estimated by Kruskal-Wallis test and 
adjusted for multiple pairwise comparisons by Dunn’s method. 
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Table 3. Association analysis between immune cell infiltration and clinic-pathological data. tNLR, 
tissue NLR; CIS, carcinoma in situ; p value estimated by # Kruskal-Wallis test or * Mann-Whitney test. 
Clinicopathological 
Variables 
 CD66b
+ TAN 
Density 
CD3+ T cells 
Density 
tNLR  
(CD66b+/CD3+) 
N° (%) Median p Median p Median p 
Total 84 (100) 78  396    
Gender   0.76 *  0.47 *  0.90 * 
Female 16 (19) 51  328  0.186  
Male 68 (81) 86  399  0.216  
Age   0.80 *  0.26 *  0.55 * 
< median 39 (46) 83  327  0.186  
≥ median 45 (54) 73  415  0.224  
pT category   0.11 *  0.003 *  0.35 * 
pT2 25 (30) 106  544  0.136  
pT3-pT4 59 (70) 60  304  0.292  
pN category   0.10 *  0.19 *  0.50 * 
pN+ 27 (32) 106  403  0.154  
pN0 57 (68) 48  357  0.234  
Overall Stage   0.14 *  0.001 *  0.32 * 
II 22 (26) 123  587  0.149  
III-IV 62 (74) 56  312  0.263  
CIS   0.46 *  0.65 *  0.90 * 
No 34 (40) 107  381  0.183  
Yes 50 (60) 68  402  0.239  
pSTAT3   0.048 *  0.43 *  0.28 * 
Low 43 (51) 51  357  0.176  
High 41 (49) 126  400  0.243  
Subtype   0.007#  0.75 #  0.06 # 
Luminal 41 (49) 51  401  0.136  
Basal 20 (24) 178  398  0.359  
Non-Type 23 (27) 60  366  0.304  
FOSL1   0.054 *  0.227 *  0.55 * 
Low 19 (22) 58  418  0.291  
High 22 (26) 155  398  0.281  
3.3. Clinical Significance of CD66b+ TAN and CD3+ T Cell Immune-Contexture in MIBC 
The clinical significance of the MIBC immune contexture was tested in term of overall survival 
(OS) and progression-free survival (PFS). The cut-offs points of low and high densities of CD3+ T cells 
and CD66b+ TAN were set at the median value for each distribution, being 396 cells/mm2 for CD3+ T 
cells and 78 cells/mm2 for CD66b+ TAN. 
Of note, a high density of both populations was associated to a better outcome at univariate 
analysis (Table 2), as also illustrated by Kaplan Meyer curves, weighted for pT category (Figure 4A–
D). Based on these findings we further extended our analysis by defining a combined immunoscore. 
Notably, the subgroup of CD3HIGHCD66bHIGH resulted in the best OS and PFS, whereas the subgroup 
of CD3LOWCD66bLOW showed the worst outcome, as indicated by Kaplan Meyer curves analysis 
weighted for pT category (Table 2 and Figure 4E–F). By a backward selection of covariates, we 
subsequently devised the optimal Cox multivariable models for OS and PFS. Remarkably, the 
immunoscore resulted significant as prognostic factor for both OS and PFS (Table 4) and its removal 
resulted in a significant worsening of the performance of each model both for OS (p < 0.001) and PFS 
(p = 0.02) applying the Likelihood-ratio test. 
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We also investigated the effect of immune cells density variations on the HR along the whole 
range of CD3+ T cells and CD66b+ TAN values. Accordingly, Cox models for OS and PFS included 
immune cells densities as continuous log-variables modelled by penalized splines (Supplementary 
Figure S1). Notably, the effect of CD3+ T cells as favorable biomarker was confirmed, following a 
linear model for both OS and PFS prediction; on the contrary, the effect of CD66b+ TAN population 
for OS display a non-linear shape. Specifically, for CD66b, the highest risk is found around the second 
quartile, whereas the lowest one is identified at both tails. This finding weakens the inference of the 
results obtained by categorizing the CD66b* TAN density as variable for OS prediction. 
 
Figure 4. Clinical significance of CD66b+ TAN and CD3+ T cells in human MIBC. Kaplan-Meier curves 
illustrate the overall (A, C and E) and progression-free (B, D and F) survival in the MIBC cohort. p 
values are estimated by log-rank test and weighted for pT category (pT2/pT3-4). 
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Table 4. Multivariable survival analysis. 
Overall Survival 
 H.R. (CI 95%) p 
Age (year) 1.041 (1.006-1.077) 0.019 
Gender (F) 2.83 (1.33 - 5.99) 0.01 
pT (pT3-4) 3.67 (1.28 – 10.51) 0.016 
CD3CD66b Immunoscore (LoLo) 6.67 (2.43 - 18.25) <0.001 
CD3CD66b Immunoscore (LoHi) 4.20 (1.35 – 13.11) 0.013 
CD3CD66b Immunoscore (HiLo) 1.59 (0.55 - 4.61) 0.40 
Progression Free Survival 
pT (pT3-4) 3.58 (1.44 - 8.93) 0.006 
CD3CD66b Immunoscore (LoLo) 3.55 (1.35 - 9.34) 0.01 
CD3CD66b Immunoscore (LoHi) 2.66 (0.91 – 7.84) 0.08 
CD3CD66b Immunoscore (HiLo) 3.69 (1.41 - 9.64) 0.008 
Reference categories: Gender, M; pT, pT2; CD3CD66b Immunoscore, HiHi. 
3.4. A Higher Density of CD66b+ TAN Is Restricted to Basal Type MIBC Expressing the Transcription 
Factor STAT3 
The immune contexture of the molecular subtype of MIBC has been poorly investigated. Data 
from previous studies indicate that luminal subtype is more likely correlated to a poor immune 
infiltrate, while basal tumors have high amount of infiltrated immune cells [14–16]. We sub-grouped 
our MIBC cohort in luminal-type, basal-type and non-type and analyzed the density of CD66b+ TAN 
and CD3+ T cells. We first classified the UBC cases on TURB (also validated on cystectomy tissue 
blocks) using a set of validated IHC markers including CK5/6, CK14, CK20 and UPK2 [52]. Based on 
this approach, the study cohort was composed of forty-two (47%) luminal-type UBC, 21 (25%) basal-
type UBC and 26 (28%) “non-type” UBC. Notably, basal type MIBCs showed a significantly (p = 0,013) 
higher density of CD66b+ TAN compared to luminal and non-type MIBCs (Figure 5 and Table 3). On 
the contrary, no differences were observed in term of CD3+ T cells density (Figure 5 and Table 3). 
It has been recently reported that the hyper-activation of the transcription factor STAT3 is central 
in the transformation and progression of basal type UBC [53]. We also contributed to this field by 
showing that the expression of pSTAT3 and downstream targets is enriched in basal type MIBC [40]. 
Of note, we found that pSTAT3+ MIBC (score 2 and 3) were significantly more infiltrated by CD66b+ 
TAN, whereas no differences were observed in term of CD3+ T cells infiltration (Figure 6 and Table 
3). We have recently shown that FOSL1 expression is strongly induced in basal-type UBC showing 
hyper-activation of STAT3 [40]. Moreover, among FOSL1-regulated genes, CXCL8 is also included 
[40]. It has been recently proposed that a FOSL1 signature including TAN-attracting CKs (CXCL8, 
CXCL6 and CXCL5) is activated in Basal B type breast cancer cell lines [54]. We found that the density 
of CD66b+ TAN slightly correlates with FOSL1 expression (Figure 7 and Table 3). 
We expanded our analysis in silico and tested the expression of a neutrophil gene signature 
(Figure 8 and Supplementary Figure S2–4) in public available datasets on the transcriptome analysis 
of large UBC cohorts. To this end we started with the TCGA RNA-seq dataset [17]. Clustering analysis 
showed that genes belonging to a neutrophil signature (obtained from [47]) were significantly over-
expressed in basal type and luminal-infiltrated MIBC, compared to luminal type (Figure 8A and 
Supplementary Figure S2). Applying the same procedure to additional independent datasets 
GSE32894 [18] and GSE124305 [45], we confirmed the enrichment of the neutrophil signature in basal 
type and infiltrated type MIBC (Figure 8B–C and Supplementary Figures S3 and S4). 
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Figure 5. Density of CD66b+ TAN and CD3+ T cells in basal and luminal MIBC. Dot plots indicating 
the density of CD3+ T cells (A) and CD66b+ TAN (B) in the MIBC cohort subdivided by molecular 
subtypes. Sections from two basal-type MIBC cases (case 70 and 49, in C–F) and two luminal-type 
MIBC cases (case 25 and 34, in G–L) are stained as labeled and counterstained with hematoxylin; 
magnification 200× (scale bar 100 micron). p values were estimated by Kruskal-Wallis test and 
adjusted for multiple pairwise comparisons. 
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Figure 6. Density of CD66b+ TAN and CD3+ T cells in human MIBC with hyper-activation of STAT3. 
Dot plots indicating the density of CD3+ T cells (A) and CD66b+ TAN(B) in the MIBC cohort based on 
pSTAT3 expression. Sections are from two pSTAT3 HIGH (case 49 and 2, in C–F) and two pSTAT3 
LOW (case 68 and 57, in G–L) MIBC cases and stained as labeled and counterstained with 
hematoxylin. Magnification: 200× (C–L), scale bar 100 micron. p values were estimated by Kruskal-
Wallis test. 
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Figure 7. Density of CD66b+ TAN and CD3+ T cells in MIBC in relation to FOSL1 expression. Dot plots 
indicating the density of CD3+ T cells (A) and CD66b+ TAN (B) in the MIBC cohort based on FOSL1 
expression. Sections are from two FOSL1 HIGH (case 49 and 14, in C–F) and two FOSL1 LOW (case 
68 and 23, in G–L) MIBC cases and stained as labeled and counterstained with hematoxylin. 
Magnification: 200× (C–L), scale bar 100 micron. p values were estimated by Kruskal-Wallis test. 
 
Figure 8. Neutrophil gene signature in UBC datasets. Plots show estimated mean score values and 
corresponding 95% confidence intervals for neutrophil GSE scores in bladder subtypes (A TCGA, B 
GSE32894, C GSE124305). Pairwise comparisons p-values were computed from linear models and 
adjusted for multiple comparisons. 
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3.5. Expression of the TAN-Attracting Chemokines in Basal-Type UBC 
TANs are recruited in the tumor environment mainly via the chemokine (CK) receptors CXCR1 
and CXCR2, although many other CKs and coupled receptors could be involved. Of note, similarly 
to the neutrophil gene signature, we found that a large set of human CKs (Supplementary Figures 
S5–10) were significantly over-expressed in basal type, (TCGA, GSE32894 and GSE124305), luminal 
infiltrated (TCGA) and infiltrated type MIBC (GSE32894), as compared to luminal type (Figure 9). 
Significantly, among top targets, the IFNγ-inducible CKs (CXCL9, CXCL10 and CXCL11) were 
included, suggesting increased local availability of IFNγ in these subtypes. Of note, many TAN 
attracting CKs [55,56], including CXCL1, CXCL2, CX3CL1 and CXCL8 resulted in being highly 
expressed (Supplementary Figures S8–10). 
No data are available on the cellular source of these CKs in MIBC. We thus tested the expression 
of CXCL1, CXCL2, CXCL8 and CX3CL1 CKs by qRT-PCR in luminal type RT4 and basal-type 5637 
cell lines (Figure 10A–D). Under resting conditions, both cell lines expressed basal levels of all the 
tested CKs, with the single exception of CXCL2 which was expressed only by the basal-type 5637 
(Figure 10C, p < 0.001). Moreover, CXCL1, CXCL2 and CXCL8 were significantly induced by pro-
inflammatory stimuli (TNF-a, IL6, IL1b) in both cell lines (Figure 10A–C). 
To test whether UBC cells can induce neutrophil migration, a transwell migration assay was 
performed using peripheral blood neutrophils from healthy donors (Figure 10E–F). Notably, under 
resting conditions, only supernatants from basal-type 5637 cells induced detectable neutrophil 
chemotaxis (Figure 10E). However, supernatants obtained from both cell lines after stimulation with 
the inflammatory cytokine cocktail, were able to induce a significantly increased neutrophil 
migration as compared to control medium, particularly if derived after 24 h of stimulation (Figure 
10F); the latter effect is likely due to the progressive in accumulation of CKs over time. 
Based on the TAN enrichment in basal-type UBC showing hyperactivation of STAT3 and FOSL1 
expression we tested the modulations of the CK by STAT3 silencing. As we demonstrated, STAT3 
silencing in these cell lines showed a marked efficiency by reducing the levels of STAT3 mRNA and 
protein of about 80% [40]. Of note, si-STAT3 in 5636 UBC line fails to modulate all CKs tested (Figure 
10G–I). 
 
Figure 9. Chemokine signature in datasets. Plots show estimated mean score values and 
corresponding 95% confidence intervals for Chemokine GSE scores in bladder subtypes (A TCGA, B 
GSE32894, C GSE124305). Pairwise comparisons p-values were computed from linear models and 
adjusted for multiple comparisons. 
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Figure 10. Modulation of TAN-attracting CK in UBC cell line. Column bars (A–D) showing the mean 
± SD of CKs mRNA relative gene expression (-ΔCt, n = 3), measured by qRT-PCR in luminal-type RT4 
and basal-type 5637 UBC cell lines. After stimulation with a cocktail of proinflammatory cytokines, a 
significant induction of the CXCL1 and CXCL8 mRNA (A, C) is observed in both UBC cell lines. 
CXCL2 is significantly enriched in basal-type 5637 UBC cell line compared to luminal-type RT4 cells 
both at resting and after stimulation (B). Column bars (E, F) showing neutrophil chemotaxis towards 
tumor-conditioned supernatants from luminal-type RT4 or basal-type 5637 UBC cell lines untreated 
(E) or stimulated for 4 or 24 h with a pro-inflammatory cytokine cocktail (F) (n = 3). Chemotaxis is 
reported as increased percentage of migrated cells (expressed as % of total cell input, mean ± SD) 
induced by tumor-conditioned supernatants over the control medium. Floating bars (G–I) showing 
that CKs’ mRNA is not modulated by siRNA STAT3 in 5637 cell line stimulated with pro-
inflammatory cytokine cocktail (mean, range; n = 3). A one-way ANOVA test was used for all 
statistical analysis and pairwise comparisons p values were adjusted for multiple comparisons; 
significant results were showed (* p < 0.05, ** p < 0.01, *** p < 0.001). INFL, with the pro-inflammatory 
cytokine cocktail (TNF-a, IL6, IL1b); supernatants, sup. 
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4. Discussion 
Urothelial bladder cancer (UBC) has limited options for systemic treatment. Recent advances in 
the understanding of their genomic landscape have proposed intrinsic subgroups based on their 
clinical, histological and biological features [8,9,17]. The two main subgroups are represented by basal 
and luminal UBC, which likely benefit from completely different treatment approach [10,12,22]. The 
study proposed here uncover a novel distinct feature of basal type UBC compared to the luminal 
type, namely a dense infiltration of CD66b+ TAN sustained by high expression of TAN-attracting 
CKs. At the cellular level, pro-inflammatory stimuli induce TAN-attracting CKs, suggesting a local 
feedback loop involving transformed cells in the organization of the immune microenvironment in 
basal type UBC. 
The most relevant finding of this study is the enrichment of CD66b+ TAN in the basal type UBC. 
This finding was not only suggested by the direct analysis of our MIBC cohort by a specific TAN 
immunohistochemical marker, but further confirmed by bio-informatic analysis of three distinct UBC 
datasets showing that a neutrophil signature is enriched in basal-type and luminal-infiltrated UBC. 
Data from the literature indicate that the immune contexture of basal type UBC is characterized by 
high amount of tumor infiltrating immune cells [14–16]. Basal-type UBC with squamous 
differentiation contain high density of NK cells, M1 macrophages and memory CD4+ T cell showing 
a Th1-polarization [57]. On the contrary luminal type UBC shows a poor immune infiltrate [14,15], 
with the exception of a subgroup known as “luminal-infiltrated” [17]. No data are proposed for the 
TAN immune contexture, even in the more recent consensus classification of UBC. Our bio-informatic 
analysis indicates that the basal-type and the “luminal infiltrated subtype” are also enriched in 
chemokines, including those attracting TAN. We subsequently found that TAN infiltration is 
abundant in MIBC showing hyperactivation of STAT3 and the downstream transcription factor 
FOSL1. STAT3 is well known as transcription factor relevant in the TAN biology [58]. Evidence 
suggests that IL-6, a cytokine known for its pro-tumor behavior via JAK2/STAT3 signaling [59], can 
attract neutrophils within an immunosuppressed microenvironment [60]. Bio-informatic findings 
from our previous study suggested that also a FOSL1 signature is enriched in basal type UBC and 
among top regulated genes CXCL8 is included [40]. In this study, we could see a trend of higher 
density of CD66b+ TAN also in FOSL1-expressing MIBC. It has been recently proposed that a FOSL1 
signature including a set of TAN-attracting CKs is activated in Basal B type breast cancer cell lines 
[54]. By analyzing basal and luminal-type BC lines, we found that a set of TAN-attracting CKs 
including CXCL1, CXCL2 and CXCL8 are potently induced by pro-inflammatory stimuli, with 
CXCL2 specifically modulated in the basal type MIBC line. Accordingly, we found that only 
supernatants from basal-type 5637 cells induced detectable neutrophil chemotaxis in resting 
conditions. It should be noted, however, that pro-inflammatory stimuli induced a significantly 
increased neutrophil migration in both luminal and basal-type UBC lines. 
By blocking STAT3 we were not able to significantly reduce the level of these CKs both resting 
or after the pro-inflammatory stimuli. This observation is, however, limited to a small set of CKs. All 
these findings suggest that hyper-activation of STAT3 measured by immunohistochemistry likely 
represent a surrogate biomarker of basal-type UBC with an active pro-inflammatory environment 
and high TAN density; however, STAT3 blockade on tumor cells, as recently proposed [40], is likely 
insufficient to dampen TAN recruitment, since STAT3-independent pathways could also be 
operative in this system. 
An enigmatic finding from this study is represented by the prognostic significance of the TAN 
density in UBC. A large series of previous studies on the neutrophil to lymphocyte ratio (NLR) in 
UBC have documented that high NLR predicts worse outcomes in patients who underwent 
cystectomy [34,35]. Recent studies have investigated the tissue ratio between neutrophils and CD8+ 
T cells in esophageal cancer [61] and in NSCLC [62]. Although in the NSCLC cohort, tissue NLR 
resulted correlated to response to ICIs, we could not detect any correlations with clinical variables or 
oncologic outcomes. 
On the contrary, very limited data are available on the clinical relevance of TAN. Liu et al. 
recently showed that elevated CD66b+ TAN correlate with an advanced T-stage, a high grade, a worse 
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recurrence-free survival (RFS) within NMIBC subgroup and a worse overall survival (OS) within all 
UBC cases [36]. Moreover, Zhou et al. have proposed that a high TAN score correlate with a poor OS 
[37]. It remains unclear how to reconcile our finding (predictive of better prognosis) with these and 
other studies [32]. Technical differences in definition of the region of interest (whole slide vs. hot spot 
or random sampling) and type of measurement (semiquantitative vs. absolute counting) could 
account. Moreover, recent advances in the characterization of TAN populations have identified TAN 
with anti-tumor function [63], particularly in the early stages cancer [64]. It should be noted that in 
UBC, a relevant anti-tumor activity of TAN has been proposed in response to BCG treatment [65], 
also supported by a recent work in a murine model [66]. Moreover, a high urinary level of TRAIL 
(tumor necrosis factor-related apoptosis-inducing ligand), a key factor for neutrophil antitumor 
activity [67], predicts favorable response to BCG therapy [68]. Finally, a high urinary level of IL-8, a 
well-known chemokine attracting neutrophil [69], is correlated to better disease free survival after 
BCG therapy [70]. Finally, genomic and proteomic approaches have proposed the existence of 
numerous TAN sub-populations [71], a level of heterogeneity that could not be resolved by a single 
marker. 
From a statistical perspective, TAN density in our study although associated with a good 
outcome, also correlate with the density of CD3+ T cells, suggesting a potential synergy of the two 
populations. However, compared to the linear predicting model followed by the CD3 density, the 
CD66 variable showed a weaker predicting power based testified by its non-linear behavior. These 
findings suggest that the identification of additional TAN biomarkers might significantly improve 
the level of immune contexture taxonomy. 
Basal-type and luminal-infiltrated subtypes are ‘hot tumors’ heavily infiltrated by T cells [57]. 
According to different consensus clustering, “luminal-infiltrated” subtypes include tumors with high 
CD8+ T cell gene signature expression, high TMB and neo-antigens and a wild-type TP53 signature 
that make them prone to better responses to ICIs. Basal-type MIBC, display a high PD-L1 expression, 
as also supported by the high level of IFN-γ inducible CKs CXCL9-11 (this study). They show a high 
frequency of TP53 mutations and a defective DNA damage repair system that make them more 
susceptible to chemotherapy with DNA-damaging agents [5]. The apoptotic effect of NeoAdjuvant 
Chemotherapy (NAC) may promote local chemokine release and subsequent immune cell 
recruitment to the tumor site facilitating the response to a second-line immune therapy [45]. Our 
findings suggest that as a whole these “hot” UBC could also be heavily infiltrated by TAN. 
5. Conclusions 
In conclusion, the analysis of TAN in prospective large-cohorts of molecularly-define BC is 
highly legitimated. Integration with surrogate biomarkers of functional activation (i.e., TRAIL or TNF 
expression) might offer additional criteria for patient stratification for appropriate co-targeting of 
TAN. 
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S1: HR estimate and CI95% for OS and PFS; Figure S2: hierarchical clustering and gene expression heatmaps of 
the neutrophil gene signature (TCGA dataset); Figure S3: hierarchical clustering and gene expression heatmaps 
of the neutrophil gene signature (GSE32894 dataset); Figure S4: hierarchical clustering and gene expression 
heatmaps of the neutrophil gene signature (GSE124305 dataset); Figure S5: hierarchical clustering and gene 
expression heatmaps of the chemokine gene signature (TCGA dataset);Figure S6: hierarchical clustering and 
gene expression heatmaps of the chemokine gene signature (GSE32894 dataset); Figure S7: hierarchical 
clustering and gene expression heatmaps of the chemokine gene signature (GSE124305 dataset); Figure S8: 
Waterfall Plot comparing Basal/Luminal Infiltrated vs. Luminal subtype for every Chemokine (TCGA dataset); 
Figure S9: Waterfall Plot comparing Basal/Infiltrated vs. Luminal subtype for every Chemokine (GSE32894 
dataset); Figure S10: Waterfall Plot comparing Basal/Immune vs. Luminal subtype for every Chemokine 
(GSE124305 dataset); Table S1: fully details (dataset) of clinical and pathology data of the retrospective MIBC 
cohort. Table S2: details of reagents for the Gene Expression Assay on UBC lines. Table S3: PMN and Chemokine 
signatures used for Analysis of the TCGA, GSE32894 and GSE124305 Datasets. Table S4: summary statistics of 
CD3 and CD66b as continuous variable. 
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